Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant <i>Acinetobacter baumannii</i> in HIV and COVID 19 infected patient: A case report

Rosa Anna Passerotto; Francesco Lamanna; Damiano Farinacci; Alex Dusina; Simona Di Giambenedetto; Arturo Ciccullo; Alberto Borghetti

doi:10.1016/j.imj.2023.02.004

Infectious Medicine 2023, 2(2): 143-147 https://doi.org/10.1016/j.imj.2023.02.004

Case Report |

Open Access | Issue | Published: 04 March 2023

Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report

Show Author's Information Hide Author's Information Rosa Anna Passerotto^{^a}(

), Francesco Lamanna^{^a}, Damiano Farinacci^{^a}, Alex Dusina^{^b}, Simona Di Giambenedetto^{^a^,^b}, Arturo Ciccullo^{^c}, Alberto Borghetti^{^b}

Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy

Infectious Diseases Unit, San Salvatore Hospital, 67100 L’Aquila, Italy

Keywords:

SARS-CoV-2, HIV, Acinetobacter baumannii, colistin, cefiderocol

Cite this article:

Passerotto RA, Lamanna F, Farinacci D, et al. Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report. Infectious Medicine, 2023, 2(2): 143-147. https://doi.org/10.1016/j.imj.2023.02.004

Download citation

EndNote(RIS)

BibTeX

304

Views

Downloads

Citations

Crossref

N/A

WoS

Scopus

N/A

CSCD

Abstract Full text About this article

Abstract

We analyzed the case of a 49-year-old woman with HIV infection off-therapy with poor viro-immunological compensation, not vaccinated for SARS-COV-2, hospitalized for lobar pneumonia and severe COVID19-related respiratory failure in intensive care unit (ICU). The hospitalization was complicated by bacteraemic ventilator-associated pneumonia (VAP) caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) isolated on pleural fluid culture, treated with colistin and cefiderocol for about 3 weeks. The molecular research of MDR-AB on transtracheal aspirate was negative following this therapy.

The aim is to show the safety, efficacy and tolerability of colistin-based combination therapy with cefiderocol for Acinetobacter baumannii infection in HIV-infected patient.

Full text

Abstract

Full text

Outline

About this article

Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report

Show Author's information Hide Author's Information Rosa Anna Passerotto^{^a}(

), Francesco Lamanna^{^a}, Damiano Farinacci^{^a}, Alex Dusina^{^b}, Simona Di Giambenedetto^{^a^,^b}, Arturo Ciccullo^{^c}, Alberto Borghetti^{^b}

Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy

Infectious Diseases Unit, San Salvatore Hospital, 67100 L’Aquila, Italy

Abstract

The aim is to show the safety, efficacy and tolerability of colistin-based combination therapy with cefiderocol for Acinetobacter baumannii infection in HIV-infected patient.

Keywords: SARS-CoV-2, HIV, Acinetobacter baumannii, colistin, cefiderocol

References(23)

[1]

GM Eliopoulos, LL Maragakis, TM Perl, Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options, Clin. Infect. Dis 46 (8) (2008) 1254–1263, doi:10.1086/529198.

DOI Google Scholar

[2]

Z Chen, Y Chen, Y Fang, et al., Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection, Sci. Rep 5 (2015) 17091, doi:10.1038/srep17091.

DOI Google Scholar

[3]

US Food and Drug Administration. 2019. Highlights of prescribing information: Fetroja (Cefiderocol). Available on: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf (accessed on 1 August 2022).

[4]

R Pascale, L Bussini, P Gaibani, et al., Carbapenem-resistant bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19) pandemic: a multicenter before-and-after cross-sectional study, Infect. Control Hosp. Epidemiol. 43 (4) (2022) 461–466, doi:10.1017/ice.2021.144.

DOI Google Scholar

[5]

S Perez, GK Innes, MS Walters, et al., Increase in hospital-acquired carbapenem-resistant Acinetobacter baumannii infection and colonization in an acute care hospital during a surge in COVID-19 admissions - New Jersey, February-July 2020, MMWR Morb. Mortal. Wkly. Rep 69 (48) (2020) 1827–1831, doi:10.15585/mmwr.mm6948e1.

DOI Google Scholar

[6]

T Nebreda-Mayoral, MA Miguel-Gómez, GA March-Rosselló, et al., Bacterial/fungal infection in hospitalized patients with COVID-19 in a tertiary hospital in the Community of Castilla y León, Spain, Enferm. Infecc. Microbiol. Clin. (Engl Ed) 40 (4) (2020) 158–165, doi:10.1016/j.eimce.2022.02.002.

DOI Google Scholar

[7]

M Bassetti, R Echols, Y Matsunaga, et al., Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicenter, pathogen-focused, descriptive, phase 3 trial, Lancet Infect, Dis 21 (2) (2021) 226–240, doi:10.1016/S1473-3099(20)30796-9.

DOI Google Scholar

[8]

C König, A Both, H Rohde, et al., Cefiderocol in Critically Ill Patients with multi-drug resistant pathogens: real-life data on pharmacokinetics and microbiological surveillance, Antibiotics (Basel) 10 (6) (2021) 649, doi:10.3390/antibiotics10101230.

DOI Google Scholar

[9]

KM Kazmierczak, M Tsuji, MG Wise, et al., In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase-and metallo-ß-lactamase-producing isolates (SIDERO-WT-2014 Study), Int. J. Antimicrob. Agents 53 (2) (2019) 177–184, doi:10.1016/j.ijantimicag.2018.10.007.

DOI Google Scholar

[10]

M Bassetti, R Echols, Y Matsunaga, et al., Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial, Lancet Infect. Dis 21 (2) (2021) 226–240, doi:10.1016/S1473-3099(20)30796-9.

DOI Google Scholar

[11]

M Falcone, G Tiseo, A Leonildi, et al., Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant acinetobacter baumannii, Antimicrob. Agents Chemother 66 (5) (2022) e0214221, doi:10.1128/aac.02142-21.

DOI Google Scholar

[12]

E Durante-Mangoni, G Signoriello, R Andini, et al., Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial, Clin. Infect Dis. 57 (3) (2013) 349–358, doi:10.1093/cid/cit253.

DOI Google Scholar

[13]

H Aydemir, D Akduman, N Piskin, et al., Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia, Epidemiol. Infect. 141 (6) (2013) 1214–1222, doi:10.1017/S095026881200194X.

DOI Google Scholar

[14]

HJ Park, JH Cho, HJ Kim, SH Han, SH Jeong, MK Byun, Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: a randomised controlled trial, J. Glob. Antimicrob. Resist. 17 (2019) 66–71, doi:10.1016/j.jgar.2018.11.016.

DOI Google Scholar

[15]

R Sirijatuphat, V Thamlikitkul, Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections, Antimicrob. Agents Chemother. 58 (9) (2014) 5598–5601, doi:10.1128/AAC.02435-13.

DOI Google Scholar

[16]

M Paul, GL Daikos, E Durante-Mangoni, et al., Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gramnegative bacteria: an open-label, randomised controlled trial, Lancet Infect. Dis. 18 (4) (2018) 391–400, doi:10.1016/S1473-3099(20)30796-9.

DOI Google Scholar

[17]

K Kaye, University of Michigan. Trial for the treatment of extensively drugresistant gram-negative bacilli. Available on: https://clinicaltrials.gov/ct2/show/NCT01597973. (accessed on 14 August 2022).

[18]

D Makris, E Petinaki, V Tsolaki, et al., Colistin versus colistin combined with ampicillin-sulbactam for multiresistant acinetobacter baumannii ventilatorassociated pneumonia treatment: an open-label prospective study, Indian J. Crit. Care Med. 22 (2) (2018) 67–77, doi:10.4103/ijccm.IJCCM_302_17.

DOI Google Scholar

[19]

W Katip, P Oberdorfer, Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant acinetobacter baumannii: a propensity score-matched analysis, Pharmaceutics 13 (2) (2021) 162, doi:10.3390/pharmaceutics13020162.

DOI Google Scholar

[20]

W Katip, S Uitrakul, P Oberdorfer, A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant acinetobacter baumannii in critically ill patients: a propensity score-matched analysis, Antibiotics 9 (10) (2020) 647, doi:10.3390/antibiotics9100647.

DOI Google Scholar

[21]

W Katip, P Oberdorfer, N Kasatpibal, Effectiveness and nephrotoxicity of loading dose colistin–meropenem versus loading dose colistin–imipenem in the treatment of carbapenem-resistant acinetobacter baumannii infection, Pharmaceutics 14 (6) (2022) 1266, doi:10.3390/pharmaceutics14061266.

DOI Google Scholar

[22]

AJ Heffernan, FB Sime, J Lipman, et al., Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: a systematic review, Int. J. Antimicrob. Agents 53 (3) (2019) 234–245, doi:10.1016/j.ijantimicag.2018.11.011.

DOI Google Scholar

[23]

T Katsube, Y Saisho, J Shimada, et al., Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects, J. Antimicrob. Chemother. 74 (7) (2019) 1971–1974, doi:10.1093/jac/dkz123.

DOI Google Scholar

About this article

Publication history

Acknowledgements

Rights and permissions

Publication history

Received: 29 November 2022

Revised: 24 February 2023

Accepted: 27 February 2023

Published: 04 March 2023

Issue date: June 2023

Copyright

Acknowledgements

Thanks to Dr. Emanuele Rando for his valuable advice and support.

Rights and permissions

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)